About Tasly
Tasly is a company based in Tianjin (China) founded in 1994 by XiJun Yan. Tasly has raised $84.5 million across 1 funding round from investors including Ally Bridge Group and BOCOM International. The company has 10,960 employees as of December 31, 2024. Tasly operates in a competitive market with competitors including Methuselah Medical Technology, Yixintang Pharmaceutical, BiggerMax, Chiatai Qingjiang Pharmaceutical and East Earth Trade Winds, among others.
- Headquarter Tianjin, China
- Employees 10960 as on 31 Dec, 2024
- Founders XiJun Yan
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Tasly Pharmaceutical Group Co. Ltd. Class A
-
Annual Revenue
$1.18 B (USD)-2.14as on Dec 31, 2025
-
Net Profit
$158.55 M (USD)15.68as on Dec 31, 2025
-
EBITDA
$264.41 M (USD)-1.06as on Dec 31, 2024
-
Total Equity Funding
$84.5 M (USD)
in 1 rounds
-
Latest Funding Round
$84.5 M (USD), Series C
Jul 12, 2018
-
Investors
Ally Bridge Group
& 1 more
-
Employee Count
10960
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Tasly
Tasly is a publicly listed company on the SSE with ticker symbol 600535 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Tasly
Tasly has successfully raised a total of $84.5M through 1 strategic funding round. The most recent funding activity was a Series C round of $84.5 million completed in July 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Tasly
Tasly has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Ally Bridge Group and BOCOM International.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and hedge fund investments in healthcare are managed.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Tasly
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tasly
Investment portfolio details for Tasly
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Tasly
Detailed financials for Tasly
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tasly Comparisons
Peer comparison for Tasly
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tasly
Tasly operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Methuselah Medical Technology, Yixintang Pharmaceutical, BiggerMax, Chiatai Qingjiang Pharmaceutical and East Earth Trade Winds, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Medical nutrition products are manufactured and supplied internationally.
|
|
| Locked | Locked | Locked |
Chinese pharmaceutical products are distributed and retailed by Yixintang Pharmaceutical.
|
|
| Locked | Locked | Locked |
Distributes high-quality Chinese medicines to businesses and partners.
|
|
| Locked | Locked | Locked |
Acts as a distributor of medicines including garlicin, celecoxib, altretamine, and others.
|
|
| Locked | Locked | Locked |
Distributes complementary and alternative medicines to support health and wellness needs.
|
Detailed competitors of Tasly
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tasly
Complete news archive for Tasly
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tasly
Tasly was founded in 1994 and raised its 1st funding round 24 years after it was founded.
Tasly is headquartered in Tianjin, China.
Tasly is a funded company, having raised a total of $84.5M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at Tasly is 10,960.
Annual revenue of Tasly is $1.18B as on Dec 31, 2025.
Manufacture and distributor of traditional Chinese medicine. It is a China-based company principally engaged in the manufacture and distribution of TCM. It provides compound Danshen dripping pills that prevent and treat coronary heart disease and angina pectoris, nourishing blood and cleaning brain granules. It also offers many medicines that help to relieve headaches, as well as bupleurum pills, huoxiangzhengqi pills, pills for stomach diseases, and andrographolide pills, among others.
Tasly's top competitors include Methuselah Medical Technology, Yixintang Pharmaceutical and BiggerMax.
Yes, Tasly is publicly traded on SSE under the ticker symbol 600535.
Tasly has 2 investors. Key investors include Ally Bridge Group, and BOCOM International.
The ticker symbol of Tasly is 600535 on SSE.